Financial Results - Lite Strategy, Inc. reported financial results for the three and six months ended December 31, 2025[6]. - The press release detailing the financial results was issued on February 17, 2026[6]. - The report does not include specific financial figures or performance metrics in the provided content[6]. - The filing does not include any financial statements or detailed exhibits[7]. - The report is not deemed "filed" under the Securities Exchange Act of 1934[6]. Company Information - The company is listed on The Nasdaq Stock Market under the symbol LITS[5]. - The company has not indicated whether it is an emerging growth company[5]. - The CEO and CFO of Lite Strategy, Inc. is Justin J. File[11]. - The address of the company's principal executive offices is 9920 Pacific Heights Blvd., Suite 150, San Diego, California 92121[2]. Product and Market Activity - No new products, technologies, market expansions, or acquisitions were mentioned in the available content[6].

Share Repurchase and Financing Activities - Lite Strategy, Inc. announced a share repurchase program authorized by the Board of Directors, allowing for the repurchase of up to $25.0 million in common stock [153]. - As of December 31, 2025, the company repurchased 137,541 shares at a weighted-average price of $1.47 per share [154]. - The company closed a $100.0 million Private Investment in Public Equity (PIPE) on July 22, 2025, issuing 23,216,898 shares at an offering price of $3.42 per share [160]. - In the three months ended December 31, 2025, the company realized gains of $0.5 million from Covered Call Options, using $0.2 million to repurchase 137,541 shares of Common Stock at an average cost of $1.47 per share [205]. - Net cash provided by financing activities for the six months ended December 31, 2025, was $96.6 million, associated with the issuance and sale of 23,216,898 shares of Common Stock and Pre-Funded Warrants [208]. - The company has no financing activities during the six months ended December 31, 2024, indicating a significant change in financing strategy [208]. Research and Development - The drug candidate pipeline includes voruciclib, an oral CDK9 inhibitor, and zandelisib, an oral PI3Kδ inhibitor, with pre-clinical development activities in nononcology disease indications commencing in Q2 FY 2026 [170][171]. - Voruciclib was previously studied in a Phase 1 trial for acute myeloid leukemia (AML) and B-cell malignancies, but all clinical trial activities were ceased in September 2024 [171]. - Research and development expenses decreased by approximately $3.4 million (98.4%) to $56,000 for the six months ended December 31, 2025, compared to $3.471 million for the same period in 2024 [197]. - Research and development expenses for voruciclib were $26,000 for the six months ended December 31, 2025, compared to $798,000 for the same period in 2024 [199]. - The company discontinued the clinical development of voruciclib in oncology as part of its strategic alternatives evaluation announced in July 2024 [204]. - Pre-clinical investigational activities in non-oncology disease indications for voruciclib commenced in the second quarter of fiscal year 2026 [204]. - The company’s future capital requirements will depend on various factors, including the costs and outcomes of regulatory reviews and clinical trials for product candidates [210]. Financial Performance and Position - General and administrative expenses decreased by $1.9 million (23.2%) to $6.4 million for the six months ended December 31, 2025, compared to $8.3 million for the same period in 2024 [200]. - Change in fair value of digital assets increased by $27.1 million (100.0%) to $27.1 million for the six months ended December 31, 2025, with no such investments in the comparable prior year period [197]. - Other (expense) income, net, decreased by approximately $2.0 million to a loss of $0.8 million for the six months ended December 31, 2025, compared to income of $1.1 million for the same period in 2024 [203]. - As of December 31, 2025, the company had $8.8 million in cash and cash equivalents and $64.0 million in unrestricted digital assets [204]. - The company has accumulated losses of $438.6 million since inception and expects to incur operating losses and generate negative cash flows from operations for the foreseeable future [204]. - For the six months ended December 31, 2025, net cash used in operating activities was $6.4 million, consisting of a net loss of $34.4 million and $1.8 million in changes in operating assets and liabilities, partially offset by $29.8 million for noncash items [206]. - Net cash used in investing activities for the six months ended December 31, 2025, was $99.4 million, primarily due to the acquisition of digital assets under the Litecoin Treasury Strategy [207]. Digital Asset Strategy - The company has initiated a Litecoin Treasury Strategy, acquiring LTC tokens to diversify reserves and enhance capital efficiency [155][163]. - The fair value of the company's digital assets, primarily LTC tokens, is subject to market fluctuations, which could materially affect investments [164]. - The company has entered into contracts with GSR Markets Ltd to write covered call options on certain LTC holdings as part of its digital asset treasury management strategy [156]. - The company aims to align with emerging financial technologies and may consider LTC mining or other crypto-focused operational activities in the future [163]. - The valuation of covered call options is marked-to-market at each reporting period, with changes recognized in the condensed consolidated statements of operations [214]. - A 10% increase in historical volatility utilized to estimate the grant date fair value of the Advisory Warrants would have resulted in an increase of $0.7 million in the grant date fair value [212]. - A 10% increase in the forward price as of December 31, 2025, would have resulted in an increase of $0.1 million in the fair value of derivative liabilities related to covered call options [216]. - The company has potential purchase obligations that could materially affect its financial position, results of operations, and cash flows, depending on future events [209].

Financial Activities - Lite Strategy, Inc. closed a $100.0 million PIPE on July 22, 2025, issuing 23,216,898 shares at an offering price of $3.42 per share[133]. - The company announced a share repurchase program of up to $25.0 million effective October 29, 2025, to be financed using available working capital[131]. - The company reported cash and cash equivalents of $10.1 million and digital assets valued at $99.4 million as of September 30, 2025[173]. - Net cash used in operating activities for the three months ended September 30, 2025, was $4.5 million, a decrease from $11.5 million in 2024[174]. - Net cash provided by financing activities for the three months ended September 30, 2025, was $96.6 million from the issuance of shares[176]. Research and Development - Voruciclib, an oral CDK9 inhibitor, completed a Phase 1 trial in September 2024 but all clinical trial efforts for it were ceased as of July 22, 2024[143][144]. - The company anticipates commencing investigational research and development activities for its drug candidate pipeline during fiscal year 2026[144]. - The company is assessing pre-clinical development programs in potentially non-oncology disease indications[130]. - Voruciclib has shown dose-dependent suppression of MCL1, which is associated with poor prognosis in AML patients[146]. - Voruciclib monotherapy study completed with 40 patients, showing no dose limiting toxicities at doses up to 200 mg[155]. - In the AML cohort, 1 patient achieved a morphologic leukemia-free state and 9 had disease stabilization lasting at least 3 months[156]. - In combination with venetoclax, 31% of patients achieved disease control at doses ≥ 100 mg, with responses lasting up to 9 months[158]. - Zandelisib development was terminated globally due to regulatory guidance, with no ongoing clinical trials[163][165]. - The company anticipates conducting additional investigational research and development activities during fiscal year 2026[173]. Expenses and Financial Management - Research and development expenses decreased by $3.2 million to $10,000 for the three months ended September 30, 2025, compared to $3.16 million in 2024[167][169]. - General and administrative expenses decreased by $2.1 million to $3.1 million for the three months ended September 30, 2025, primarily due to reduced personnel costs[170]. Strategic Initiatives - The Litecoin Treasury Strategy was initiated in August 2025, focusing on acquiring LTC tokens to diversify reserves and enhance capital efficiency[132][136]. - The company has entered into various agreements with advisors to help deploy its Litecoin Treasury Strategy, including a placement agency agreement and an asset management agreement[134]. - The evaluation of strategic alternatives included the potential for out-licensing opportunities or sale of existing programs[135]. - The company is committed to long-term innovation in capital structure and financial technology, including potential LTC mining activities[136]. Accounting and Compliance - The company has no changes in significant accounting policies or critical accounting estimates since June 30, 2025, except for those related to Digital Assets and Warrants[178]. - A 10% increase in historical volatility would have resulted in a $0.7 million increase in the grant date fair value of the Advisory Warrants[181]. - A 10% increase in assets under management would have led to a $0.2 million increase in the fair value of liabilities settled through the issuance of GSR Pre-Funded Warrants[182]. - The company has payment obligations under remaining license agreements contingent upon achieving specified development, regulatory, and commercial milestones[180]. - The company recognizes an asset for services not yet rendered and amortizes the fair value over the requisite service period[181]. - The company is obligated to reimburse clinical trial costs under future collaboration agreements, if any[180]. - The company has costs associated with securing manufacturing arrangements for development activities and commercial production[180]. - The company is required to make royalty payments in connection with the sales of products developed under license agreements[180]. - The company discusses critical accounting estimates in its Management's Discussion and Analysis section of the 2025 Annual Report[178]. - The company evaluates equity instruments issued for services based on fair value determined using an option pricing model or the fair value of liabilities incurred[179].

Core Insights - Lite Strategy, Inc. has authorized a $25 million share repurchase program, marking a significant shift in its treasury management approach [2][3] - The company aims to enhance shareholder value by buying back shares when prices fall below market-adjusted net asset value (mNAV) and selling shares when prices exceed mNAV [5][9] Company Overview - Lite Strategy is the first U.S.-listed company to hold Litecoin as its primary reserve asset, transitioning from a focus on drug development to digital asset management [3][14] - The new buyback program aligns with the company's strategy to redefine treasury management by integrating digital assets with traditional financial practices [8][14] Share Repurchase Program Details - The $25 million repurchase authorization is effective immediately, allowing for flexibility in execution without set price targets or timelines [6][12] - The program may utilize a Rule 10b5-1 trading plan, enabling share repurchases during blackout periods, funded by existing working capital [7][12] Market Reaction and Shareholder Impact - The market responded positively to the buyback announcement, with Lite Strategy's stock price increasing by over 7.7% [12] - The repurchase program is expected to enhance shareholder value by increasing earnings per share as shares are bought back below intrinsic value [12][19] Institutional Confidence and Governance - The shift in strategy reflects growing institutional interest in active crypto management, with support from large investors like GSR [15][16] - The Board's commitment to long-term shareholder value and adherence to Nasdaq's governance standards reinforces the company's credibility [16] Future Considerations - Investors will monitor the implementation of the Rule 10b5-1 plan, the volume of shares repurchased, and the reinvestment of proceeds from ATM sales into Litecoin [18][19] - Quarterly filings will provide insights into the effectiveness of the hybrid treasury model and its impact on shareholder value [19]

Core Insights - GSR has agreed to acquire Equilibrium Capital Services, a registered broker-dealer, to gain licensed access to U.S. securities markets [1][5] - The acquisition aims to enhance GSR's ability to serve institutional clients seeking regulated exposure to digital assets [2][7] - The deal is part of GSR's broader strategy to expand its footprint in regulated markets amid increasing regulatory scrutiny [4][6] Company Strategy - GSR plans to leverage Equilibrium's registration to offer brokerage services compliant with U.S. securities laws [2][5] - The acquisition is expected to strengthen GSR's U.S. presence and facilitate the development of regulated investment products for American institutions [8] - GSR has previously partnered with DigiFT and invested in Maverix Securities to enhance its offerings in tokenized assets and structured products [4] Industry Context - The acquisition reflects a trend among crypto firms to integrate into traditional regulatory frameworks as U.S. agencies increase scrutiny [6] - Institutional interest in digital assets is growing, particularly in tokenized funds and real-world asset products, prompting firms to seek broker-dealer licenses [7]

Financial Performance - The company has incurred significant losses since inception and anticipates continued losses in the foreseeable future, particularly after discontinuing clinical programs involving voruciclib [137]. - For the fiscal year ended June 30, 2025, the company incurred a net loss of $15.9 million, compared to a net income of $17.8 million for the fiscal year ended June 30, 2024, resulting in an accumulated deficit of $404.2 million as of June 30, 2025 [138]. - The company expects that R&D costs will increase if development activities are resumed in the future, leading to continued operating and net losses [139]. - Future financial results may fluctuate significantly based on the timing of resuming drug candidate development, clinical trials, and related agreements [140]. - The company anticipates that its current unrestricted cash and cash equivalents will be sufficient to fund its operating plan for at least the next 12 months, but R&D expenses will resume if pre-clinical development of voruciclib and zandelisib is restarted [145]. - Future funding requirements will depend on various factors, including potential acquisitions or investments in complementary businesses, products, and technologies [146]. - The company may need to raise additional capital to continue drug development if activities are resumed, and there is uncertainty regarding the availability of funding on acceptable terms [144]. - The company is exposed to risks from negative economic conditions that may affect its ability to secure funding and collaborate with partners [159]. Drug Development and Clinical Trials - The evaluation of strategic alternatives led to the discontinuation of clinical development for voruciclib as of July 22, 2024, while nonclinical activities continued [15]. - Voruciclib, an oral CDK9 inhibitor, completed a Phase 1 trial in September 2024, but all clinical efforts were ceased in July 2024 [25][34]. - The company anticipates conducting further investigational research and development on its drug candidate pipeline in the coming months [15]. - The company has discontinued clinical programs as of July 2024 while exploring strategic alternatives, and there is uncertainty regarding the success of any future drug candidates [147]. - The drug candidate pipeline includes voruciclib, an oral CDK9 inhibitor, and zandelisib, an oral, once-daily, selective PI3Kδ inhibitor [212]. - The company aims to evaluate drug candidates in combinations with standard-of-care therapies to address medical needs and improve patient benefits [211]. Regulatory Compliance and Challenges - The FDA requires extensive regulatory compliance for pharmaceutical products, including nonclinical and clinical testing, which can be time-consuming and costly [65][84]. - The company must submit an investigational new drug (IND) application, which becomes effective 30 days after submission unless the FDA raises concerns [70]. - Clinical trials are conducted in three phases, with Phase 3 requiring two trials for FDA approval under normal circumstances [76]. - The company may face significant costs related to compliance with FDA regulations, including user fees and annual program fees [83]. - Products designated as fast track may benefit from expedited development and review processes, including rolling submissions [90]. - Accelerated approval may be granted based on evidence of clinical effect on a surrogate endpoint, but requires post-marketing studies to verify clinical benefit [91]. - The company must maintain compliance with ongoing FDA requirements post-approval, including reporting adverse effects and adhering to quality control standards [86]. - Noncompliance with FDA regulations could result in severe consequences, including product recalls and penalties [87]. - The company is exploring breakthrough therapy designation for products intended to treat serious diseases, which may lead to intensive FDA guidance and expedited review processes [92]. - If a product is approved for a serious condition, it may qualify for priority review, reducing the FDA's review timeline from ten months to six months [94]. - The company may face challenges in obtaining coverage and reimbursement from third-party payors, which could impact future sales of approved products [107]. - The company must navigate potential changes in FDA approval standards and regulatory requirements that could impact product approvals and market competitiveness [109]. - The centralized procedure for marketing authorizations in the EU is mandatory for certain oncology products, which may apply to the company's biotechnology-developed products [111]. - The company may face delays in securing regulatory approvals in the EU, similar to challenges experienced in the U.S. [112]. - The company is required to list patents covering its drugs with the FDA, which are published in the Orange Book, impacting competition and generic drug applications [95]. - The company may not be able to take full advantage of patent term extensions or marketing exclusivity provisions, which could expose it to competition [101]. Leadership and Corporate Governance - The company appointed Justin J. File as Acting CEO and Frederick W. Driscoll as Chairperson of the Board following leadership changes in August 2024 [15]. - The terminated merger agreement with Infinity Pharmaceuticals did not receive necessary stockholder approval on July 23, 2023 [23]. Cybersecurity and Data Protection - The company has established policies for assessing and managing material risks from cybersecurity threats, integrating these into overall risk management systems [189]. - The Audit Committee oversees the implementation of the cybersecurity risk management program and receives annual reports on cybersecurity risks [196]. - The company has not encountered cybersecurity challenges that have materially impaired its operations or financial standing [194]. - Security breaches or cyberattacks could lead to significant losses of Litecoin, adversely affecting financial condition and operations [134]. - The company must comply with evolving privacy and data protection regulations, which may impose additional costs and liabilities [162]. - The company is implementing new standard contractual clauses for data transfer from the EEA to the U.S. following European Commission guidelines issued on June 4, 2021 [163]. - Compliance with the California Consumer Privacy Act (CCPA) and amendments from the California Privacy Rights Act (CPRA) effective January 1, 2023, may significantly impact business activities and incur substantial compliance costs [164]. Cryptocurrency and Market Conditions - The price of Litecoin has been highly volatile, trading between $50.43 and $146.61 per Litecoin over the past 12 months, with a recent range of $63.75 to $106.15 in Q2 2025 [124]. - The introduction of central bank digital currencies (CBDCs) could reduce the demand for private-sector cryptocurrencies like Litecoin, impacting market opportunities [126]. - Regulatory developments regarding crypto assets may adversely affect the business, financial condition, and results of operations, with potential new laws impacting Litecoin's price [127]. - The U.S. capital markets are experiencing extreme volatility, which could adversely affect the company's financial condition and access to capital markets [171]. Shareholder Returns and Dividends - The company announced a cash dividend of $1.75 per share, totaling $11.7 million, paid on December 6, 2023, recorded as a reduction of additional paid-in capital [21]. - The company does not intend to pay cash dividends on its common stock, focusing instead on retaining earnings for business development [176]. - The company does not anticipate paying additional cash dividends in the foreseeable future and intends to retain available funds to support operations [206]. - On November 6, 2023, the Board declared a special cash dividend of $1.75 per share, totaling $11.7 million, to be paid on December 6, 2023 [206]. Employee Relations - As of June 30, 2025, the company had four employees engaged in various support roles, with no labor union representation [118]. - The company has not experienced a work stoppage and maintains positive relations with its employees [121]. Environmental and Safety Compliance - The company is subject to numerous environmental, health, and safety laws, and failure to comply could result in significant fines and operational impairments [166].

Company Overview - Lite Strategy Inc. (NASDAQ: LITS), previously known as MEI Pharma, Inc. and traded under the ticker "MEIP," was focused on oncology with two drug candidates, vorucliclib and ME-144, which were aimed at oncology combination therapies [1]. Analyst Background - The article includes a brief background of Myriam Hernandez Alvarez, who holds multiple degrees in engineering, computer science, business management, and computer applications, indicating a strong academic foundation relevant to the analysis [1]. Disclosure Information - The article contains disclosures stating that the analyst has no stock or derivative positions in the companies mentioned and has no plans to initiate any such positions within the next 72 hours [2]. - It is noted that the opinions expressed are independent and not influenced by any business relationships with the companies discussed [2].

Company Communication - MEI Pharma expresses appreciation for Litecoin [1]

Company Strategy - MEI Pharma adopted a Litecoin Treasury Strategy, becoming the first public US company to do so [1] - The strategy aims to bring Litecoin, described as "the people's currency," to institutional portfolios [1] Litecoin Acquisition - MEI Pharma acquired 929,548 Litecoins (LTC) [1] - The total investment was approximately $100 million [1] - The average acquisition price was about $107.58 per Litecoin [1] Partnerships - The Litecoin Treasury Strategy involved collaboration with @SatoshiLite and @GSR_io [1]

Company Communication - MEI Pharma is seeking information about Litecoin (LTC) [1] Cryptocurrency - Litecoin (LTC) is mentioned in the context of MEI Pharma's inquiry [1]